We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M Turnover 60.61%
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
+2.11%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$66.4M
AUM Growth
+$8.29M
Cap. Flow
+$2.99M
Cap. Flow %
4.5%
Top 10 Hldgs %
32.21%
Holding
297
New
108
Increased
49
Reduced
51
Closed
72
Avg Time Held Equity + Options
0.5 years
Top 10 Avg Time Held Equity + Options
0.1 years
Top 20 Avg Time Held Equity + Options
0.1 years
Avg Time Held Equity only
0.5 years
Top 10 Avg Time Held Equity only
0.2 years
Top 20 Avg Time Held Equity only
0.2 years

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$3.53M
2
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$2.94M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$2.18M
4
ARAV
Aravive, Inc. Common Stock
ARAV
+$1.54M
5
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$1.37M

Top Sells

Rank Stock Value
1
GIS icon
General Mills
GIS
+$2.52M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$2.31M
3
AMGN icon
Amgen
AMGN
+$2.08M
4
ABT icon
Abbott
ABT
+$1.72M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$1.56M

Sector Composition

Rank Sector Weight
1 Healthcare 43.45%
2 Miscellaneous 41.8%
3 Consumer Discretionary 7.1%
4 Consumer Staples 6.25%
5 Communication Services 0.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
REGN icon
151
CALL
Regeneron Pharmaceuticals
REGN
$83.1B
$29K 0.04%
7,500
+2,500
+50% +$1.19M
2015 Q4
7 quarters
HAIN icon
152
CALL
Hain Celestial
HAIN
$21.1M
$28K 0.04%
10,000
+4,100
+69% +$169K
2017 Q2
1 quarter
HSY icon
153
PUT
Hershey
HSY
$34.1B
$28K 0.04%
6,800
– –
2017 Q2
1 quarter
AVXS
154
PUT
DELISTED
AveXis, Inc. Common Stock
AVXS
$28K 0.04%
+15,000
New +$1.35M
2017 Q3
0 quarters
CLX icon
155
PUT
Clorox
CLX
$10.6B
$26K 0.04%
5,500
-30,100
-85% -$4.04M
2016 Q4
3 quarters
K icon
156
PUT
DELISTED
Kellanova
K
$26K 0.04%
5,325
-20,342
-79% -$1.28M
2016 Q4
3 quarters
PTCT icon
157
PUT
PTC Therapeutics
PTCT
$5.25B
$25K 0.04%
+25,000
New +$489K
2017 Q3
0 quarters
ALNY icon
158
PUT
Alnylam Pharmaceuticals
ALNY
$30.9B
$24K 0.04%
38,700
+18,700
+94% +$1.6M
2016 Q1
6 quarters
JUNO
159
CALL
DELISTED
Juno Therapeutics, Inc.
JUNO
$24K 0.04%
+12,300
New +$419K
2017 Q3
0 quarters
EXAS icon
160
PUT
DELISTED
Exact Sciences
EXAS
$23K 0.03%
+7,000
New +$282K
2017 Q3
0 quarters
BHC icon
161
PUT
Bausch Health
BHC
$2.4B
$22K 0.03%
25,500
-9,500
-27% -$144K
2015 Q4
7 quarters
EXAS icon
162
CALL
DELISTED
Exact Sciences
EXAS
$22K 0.03%
+7,000
New +$282K
2017 Q3
0 quarters
PLCE icon
163
CALL
Children's Place
PLCE
$23.6M
$22K 0.03%
+11,400
New +$1.23M
2017 Q3
0 quarters
LOXO
164
PUT
DELISTED
Loxo Oncology, Inc
LOXO
$22K 0.03%
+3,000
New +$233K
2017 Q3
0 quarters
BHC icon
165
CALL
Bausch Health
BHC
$2.4B
$20K 0.03%
25,500
-14,100
-36% -$213K
2015 Q4
7 quarters
IBB icon
166
CALL
iShares Biotechnology ETF
IBB
$10.9B
$20K 0.03%
12,000
-33,000
-73% -$3.53M
2017 Q1
2 quarters
MOS icon
167
The Mosaic Company
MOS
$5.68B
$20K 0.03%
+933
New +$20.2K
2017 Q3
0 quarters
ARAV
168
CALL
DELISTED
Aravive, Inc. Common Stock
ARAV
$19K 0.03%
+56,183
New +$5.67M
2017 Q3
0 quarters
GDX icon
169
PUT
VanEck Gold Miners ETF
GDX
$26.2B
$18K 0.03%
+6,000
New +$139K
2017 Q3
0 quarters
QSR icon
170
PUT
Restaurant Brands International
QSR
$26.2B
$18K 0.03%
+10,000
New +$618K
2017 Q3
0 quarters
ALXN
171
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$18K 0.03%
+2,500
New +$340K
2017 Q3
0 quarters
PF
172
CALL
DELISTED
Pinnacle Foods, Inc.
PF
$18K 0.03%
26,700
+7,000
+36% +$415K
2017 Q2
1 quarter
AERI
173
CALL
DELISTED
Aerie Pharmaceuticals
AERI
$17K 0.03%
+16,000
New +$873K
2017 Q3
0 quarters
AER icon
174
CALL
AerCap
AER
$22.7B
$16K 0.02%
+10,000
New +$490K
2017 Q3
0 quarters
CYTK icon
175
PUT
Cytokinetics
CYTK
$8.89B
$15K 0.02%
+5,000
New +$68.3K
2017 Q3
0 quarters
5 6
7
8 9

Similar funds

MC
Micawber Capital Seattle, Washington $62.9M AUM 20.32% 1-Year Est. Return
FIM
Friedberg Investment Management Houston, Texas $61.9M AUM 20.07% 1-Year Est. Return
TLIC
Thai Life Insurance Company Bangkok, Thailand $71M AUM 20.14% 1-Year Est. Return
MKCM
Mount Kellett Capital Management New York $61M AUM 12.22% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
MFM
Marianas Fund Management New York $58.1M AUM 10.84% 1-Year Est. Return
VE
Vega Energy New York $75.5M AUM 15.36% 1-Year Est. Return
GFWEV
G.F.W. Energy VIII Irving, Texas $76.3M AUM 11.41% 1-Year Est. Return

FT Options's Q3 2017 Portfolio in Review

As of Q3 2017, FT Options held 297 positions worth $66.4M, up 14% from $58.1M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

FT Options deployed $2.99M of net new capital in Q3 2017, opening 108 new positions and adding to 49 existing holdings. Its largest new stake was Incyte: 27,887 shares worth $3.26M.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 43% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.

On the sell side, the largest reduction was General Mills, an estimated $2.52M trimmed.

  • FT Options's largest Q3 2017 buy was Incyte: 27,887 shares worth $3.26M.
  • FT Options added most to Sio Gene Therapies Inc. Common Stock in Q3 2017, an estimated $1.37M increase.
  • FT Options's biggest Q3 2017 reduction was General Mills, cutting an estimated $2.52M.
  • FT Options fully exited Portola Pharmaceuticals, Inc. in Q3 2017, selling an estimated $2.31M.
  • FT Options's ten largest holdings make up 32% of its $66.4M portfolio in Q3 2017.
  • FT Options opened 108 new positions and closed 72 in Q3 2017.
  • FT Options's portfolio value rose 14% quarter-over-quarter to $66.4M.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.